| I-078 Robert de Mooij A quantitative comparison of tumor sub-model variants in a minimal PBPK model for early clinical dose projections of antibody therapeutics in oncology Wednesday 10:20-11:50 |
| II-018 Burak Kuersad Guenhan Evaluating the utility of dose/exposure-response modeling for dose optimization in oncology Wednesday 15:20-16:50 |
| II-042 Ana Homšek External evaluation of selected infliximab population pharmacokinetic models on patients with fistulizing Crohn’s disease Wednesday 15:20-16:50 |
| III-070 Zvonimir Petric Population Pharmacokinetic Model of Apovincaminic Acid (AVA) — an Exposure Proxy of Vinpocetine Thursday 09:50-11:20 |
| III-099 Maša Roganović External evaluation of published population pharmacokinetic models of adalimumab in inflammatory bowel disease patients Thursday 09:50-11:20 |
| III-107 Aymara Sancho Does shrinkage on exposure metrics truly impair E-R analysis? Thursday 09:50-11:20 |
| IV-037 Veena Thomas Utility of Physiologically-based Pharmacokinetic Model to Predict Inter-Antibody Variability in Monoclonal Antibody Pharmacokinetics Thursday 15:00-16:30 |
| IV-108 Renwei Zhang Impact of censoring on non-linear effect modeling of aggregate-level survival data Thursday 15:00-16:30 |
